Keros Therapeutics, Inc. (KROS)

NASDAQ: KROS · IEX Real-Time Price · USD
37.62
+1.31 (3.61%)
Sep 30, 2022 4:00 PM EDT - Market closed
3.61%
Market Cap 968.98M
Revenue (ttm) 20.00M
Net Income (ttm) -78.69M
Shares Out 25.76M
EPS (ttm) -2.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 138,236
Open 36.20
Previous Close 36.31
Day's Range 35.68 - 39.02
52-Week Range 24.38 - 68.29
Beta 1.28
Analysts Buy
Price Target 95.88 (+154.9%)
Earnings Date Nov 2, 2022

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing smal... [Read more...]

Industry Biotechnology
IPO Date Apr 8, 2020
Employees 97
Stock Exchange NASDAQ
Ticker Symbol KROS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for KROS stock is "Buy." The 12-month stock price forecast is 95.88, which is an increase of 154.86% from the latest price.

Price Target
$95.88
(154.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 P...

LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializa...

2 weeks ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring sideroblast-positive and non-RS patients; 44% of high tra...

1 month ago - GlobeNewsWire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pu...

LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

3 months ago - GlobeNewsWire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Dat...

LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

3 months ago - GlobeNewsWire

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 i...

LEXINGTON, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializati...

4 months ago - GlobeNewsWire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Am...

LEXINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development an...

4 months ago - GlobeNewsWire

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializati...

4 months ago - GlobeNewsWire

Keros Therapeutics Reports First Quarter 2022 Financial Results

LEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development an...

4 months ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

LEXINGTON, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

6 months ago - GlobeNewsWire

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

7 months ago - GlobeNewsWire

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Prec...

Lexington, Mass. – December 13, 2021 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors under the heading "A Phase 2,...

9 months ago - GlobeNewsWire

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Dat...

LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

9 months ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

10 months ago - GlobeNewsWire

Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Pre...

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

10 months ago - GlobeNewsWire

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associate...

LEXINGTON, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

11 months ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

1 year ago - GlobeNewsWire

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with ...

LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire

Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializati...

1 year ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development an...

1 year ago - GlobeNewsWire

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

LEXINGTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

1 year ago - GlobeNewsWire

Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of...

LEXINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

1 year ago - GlobeNewsWire

Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

LEXINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire

Last Week's Notable Insider Buys: Avis, Biglari And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other symbols: CARBHGTHXORGOREYNWTRH
1 year ago - Benzinga

Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to ...

LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 year ago - GlobeNewsWire